Neurogene (NGNE) Tax Provisions (2013 - 2014)
Neurogene (NGNE) reported Tax Provisions of -$222.0 for Q3 2014, up 95.6% on a YoY basis from -$113.5 in Q3 2013, and down 604.55% quarter-over-quarter from $44.0 in Q4 2013.
Neurogene (NGNE) Tax Provisions (2013 - 2014) Analysis & Trends
Neurogene has reported Tax Provisions for 2 years, with the latest figure at -$222.0 in Q3 2014.
- For the quarter ending Q3 2014, Tax Provisions rose 95.6% year-over-year to -$222.0; the trailing twelve-month figure through Dec 2014 stood at -$5222.0 (changed N/A YoY), and the FY2014 full-year result was -$222.0, up 95.56% from the prior year.
- Tax Provisions for Q3 2014 stood at -$222.0, down from $44.0 in the prior quarter.
- The five-year high for Tax Provisions was $44.0 in Q4 2013, with the low at -$5044.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | -222.00 |
| Dec 31, 2013 | 44.00 |
| Sep 30, 2013 | -5,044.00 |